title: [Somatostatin and regulation of the secretion of growth hormone].
abstract: GH secretory bursts are due to the combination of a pulsatile GRF release and a decreased Somatostatin secretion in hypophysial portal blood. In the intermediary periods, low plasma GH levels depend on the tonic release of hypothalamic Somatostatin. Experimental studies suggest that alterations in hypothalamic Somatostatin are involved in changes of GH secretion observed under physiological (foetal life, aging, stress), pharmacological (beta-blocking agents) and physiopathological conditions (starvation, obesity, diabetes). The Somatostatin analogue SMS 201-995 induces a long-lasting inhibition of GH secretion and may be useful in the treatment of acromegalic patients.
mesh_terms: D000818:Animals; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism*; D010902:Pituitary Gland / Q000378:metabolism*; D013004:Somatostatin / Q000502:physiology* / Q000627:therapeutic use
chemical_list: D013004:Somatostatin; D013006:Growth Hormone
vernacular_title: Somatostatine et régulation de la sécrétion d'hormone de croissance.